Yu.L. Mizernitskiy

Yu.L. Mizernitskiy

Auto-generated profile, based on publicly available information

Yu.L. Mizernitskiy

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ANAndrey A. Novak
Andrey A. Novak
YMYuriy L. Mizernitskiy
Yuriy L. Mizernitskiy
ЮМЮ. Л. Мизерницкий
Ю. Л. Мизерницкий
This review article provides an up-to-date understanding of primary ciliary dyskinesia (immotile-cilia syndrome) and its particular variant, Cartagener syndrome, a genetically determined pathology leading to chronic inflammatory lesions of the respiratory tract, hearing organs, and impaired fertile function. This orphan disease is not well known to the general medical community. Primary ciliary dyskinesia is a rare hereditary disease of the group of ciliopathies that is based on a genetically determined defect in the ultrastructure of the cilia of the respiratory tract epithelium and similar structures, leading to impaired motor function. Various step-by-step algorithms have been proposed to verify the diagnosis, the obligatory components of which are assessment of the motor ability of the cilia of the atopic epithelium, nasal nitric oxide (nNO) level, electron microscopic examination of a bronchial mucosal biopsy specimen, and genetic examination. There is no gold standard for diagnosis of primary ciliary dyskinesia. Diagnostic search in patients should be complex and consist of certain stages. Currently, therapeutic strategies for primary ciliary dyskinesia are based on approved clinical guidelines. In many countries, the therapy of patients with primary ciliary dyskinesia is based on treatment protocols for patients with cystic fibrosis, despite the obvious differences in these diseases. The main goal of therapy is adequate airway clearance, control and prevention of infectious diseases, and elimination of potential airway exposure to various types of pollutants, including tobacco smoke. The article describes the clinic, characteristic symptoms of the disease, its prevalence and genetic aspects, discusses the problems of diagnosis, treatment, prognosis and monitoring of these children, as well as the need for a national register of patients with this pathology.

11 December 2023 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
SASergey Avdeev
Sergey Avdeev
TKTatiana Kyian
Tatiana Kyian
YMYu. L. Mizernitskiy
Yu. L. Mizernitskiy
ЮМЮ. Л. Мизерницкий
Ю. Л. Мизерницкий
Primary ciliary dyskinesia (PCD) is a rare hereditary disease from the group of ciliopathies with extensive locus and allelic heterogeneity (ORPHA 244, 98861; OMIM 242650, 244000). This disease is inherited by autosomal dominant or autosomal recessive type and, less often, by X-linked type (OMIM 300424). Retinitis pigmentosa develops in the X-linked PCD variant. The overall minimum global prevalence of PCD according to European data is 1 : 7554. There is no generally accepted classification of PCD in the international classification of diseases (ICD), 10th revision. PCD is not presented in ICD-10 as a separate medical entity, and the code Q32.4 – Other congenital bronchial anomalies – is used for coding. In the new edition of ICD-11, the code LA75.Y is highlighted – Other specified structural abnormalities of the lungs.Primary ciliary dyskinesia. However, there is no generally accepted classification of PCD. The aim of the study was to develop a classification of primary ciliary dyskinesias to improve the efficiency of medical care for patients during follow-up.Methods. European and Russian clinical recommendations, as well as ICD 10th and 11th revision, Classification of Respiratory Insufficiency (2020), Order of 27.08.19 No.585n “On classifications and criteria used in the implementation of medical and social expert assessment of citizens by federal state institutions of medical and social expert assessment” (as amended on 06.10.21) were used to create the classification.Results. The classification of PCD was created and can be recommended for use in clinical practice. The classification was based on the presence or absence of the Sievert – Kartagener syndrome (complete, not complete), as well as clinical and instrumental characterization of bronchopulmonary changes based on the presence of chronic obstructive bronchitis, bronchiectasis (specifying the type and localization), pneumofibrosis with the process activity (exacerbation, remission), and the degree of respiratory failure. It is recommended to take into account extrapulmonary manifestations of PCD, such as rhinosinusitis, media otitis, congenital heart defect, and complications. It is recommended to use the PICADAR (PrImary CiliAry DyskinesiA Rule) score and to include the results of video microscopy, DNA diagnosis, and microbiological examination in the diagnosis.Conclusion. The application of the proposed classification can be useful in the dynamic observation of the patient, therapy and in the conduct of medical and social expert assessment.

24 November 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
YMYu. L. Mizernitskiy
Yu. L. Mizernitskiy
ИМИ. М. Мельникова
И. М. Мельникова
ЮМЮ. Л. Мизерницкий
Ю. Л. Мизерницкий
The article presents data on the etiology, modern methods for diagnosis and treatment of respiratory system diseases and examines in detail cough as the main symptom. Particular attention is paid to hypertussivity, which is defined as a cough that occurs in the absence of obvious reasons. In addition, the emphasize was put on the role of anatomical and physiological features in the development and characteristics of cough, especially in young children. The authors draw attention to the complex mechanism of the cough, which development involves many body systems such as nervous, immune, endocrine and respiratory. The article describes the main treatment methods, drugs prescribed to the patients with cough, which are divided into «antitussive» drugs used as cough suppressants and «protussive» drugs used in situations, in which mobilization of secretions is desired, combined drugs. The role of new combined drugs, in particular, Rengalin, which affects the central and peripheral links of the cough reflex, was noted.

24 November 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
YMYu. L. Mizernitskiy
Yu. L. Mizernitskiy
NDN. L. Dorovskaya
N. L. Dorovskaya
ИМИ. М. Мельникова
И. М. Мельникова
ЮМЮ. Л. Мизерницкий
Ю. Л. Мизерницкий
The inflammatory process in the bronchial mucosa of various origins (infectious, allergic, irritative, etc.) cause changes in the sputum production and its rheological properties, slowing of mucociliary clearance. Mucoactive therapy is one of the important components of the management of bronchopulmonary diseases. The article provides a detailed review of the modern literature, as well as the authors’ own experience regarding the cough therapy methods, including techniques used in the bronchial obstructive syndrome. The use of combination drugs, which simultaneously affect various pathogenetic mechanisms of inflammation and cough, including those in the respiratory diseases with bronchial obstructive syndrome, becomes a promising direction of mucoactive therapy. Due to relative safety and clinical efficacy, the modern combination therapy, including a fixed-dose combination of salbutamol, bromhexine, guaifenesin (Ascoril, Ascoril expectorant), is increasingly becoming the drug of informed choice in mild bronchial obstruction in childhood in pediatric practice.

15 July 2022 in Perm Medical Journal
Verified
Journal Article
Open access
PDF file
IMI. M. Melnikova
I. M. Melnikova
NDN. L. Dorovskaya
N. L. Dorovskaya
ADA. P. Dmitrieva
A. P. Dmitrieva
YMYu. L. Mizernitskiy
Yu. L. Mizernitskiy
МЛМизерницкий Ю. Л.
Мизерницкий Ю. Л.
Objective. To determine the trends in the structure and assess medical, social and clinical aspects of the consumption of tobacco and nicotine-containing products among adolescents aged 1417. Material and methods. During the study, 352 adolescents aged 14 to 18 years studying in urban (n = 202) and rural (n = 150) schools of Yaroslavl region were surveyed in 20202021. Statistical processing of the data was carried out using computer programs "Statistica" v.10.0. Results. The survey of teenagers revealed a fairly high prevalence not only of active tobacco smoking (tried 37 %, actively smoked 30 % of adolescents), but also the use of "new" nicotine-containing products (vape, hookah, electronic cigarettes, snus, snuff) (tried 38 %, actively used 7 % of teenagers). The structure of active tobacco use and NRTI use was found to differ by the place of residence. Active tobacco use accounted for 46.7 % of rural adolescents and 19.8 % of urban residents (p 0,01). Conclusions. In modern adolescents, along with tobacco smoking, a negative trend has been detected to increase the use of nicotine-containing products, especially hookah. This substantiates the need to improve educational anti-nicotine programs, to introduce a system of regular regional monitoring of the prevalence of traditional and new nicotine-containing products use among children and adolescents in order to make quick and effective decisions.

9 July 2023 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
SASergey Avdeev
Sergey Avdeev
NGNatalia Geppe
Natalia Geppe
NINatalya I. Ilyina
Natalya I. Ilyina
IDIrina V. Demko
Irina V. Demko
AZAlexander V. Zhestkov
Alexander V. Zhestkov
ИИИльина Наталья Ивановна
Ильина Наталья Ивановна
Under the auspices of the Russian Association of Allergists and Clinical Immunologists and the Russian Pediatric Respiratory Society, an expert meeting on Leukotriene receptor antagonists in the treatment of bronchial asthma was held. Asthma is a common noncommunicable chronic disorder of the airways, characterized by variable and recurring symptoms, airflow obstruction, bronchial hyper-responsiveness, and underlying inflammation. The creation and widespread use of inhaled corticosteroids and other innovative classes of drugs for treating bronchial asthma have remarkably affected the ability to achieve control over the course of the disease. Regardless, in most European countries, more than half of patients with bronchial asthma have suboptimal disease control. Recently, a class of leukotriene receptor blockers that contribute to the suppression of chronic allergic inflammation in patients with asthma has been actively studied. The majority of studies confirmed the usefulness of montelukast as monotherapy and as an add-on therapy to inhaled corticosteroids in mild to moderate asthma across all age groups. However, experts noted that in practical medicine, healthcare providers continuously inquire about the effectiveness and safety of this class of medicines in patients with bronchial asthma. In this consensus document, the experts considered the importance of providing an answer to several topical questions regarding the use of antileukotriene therapy in clinical practice.